AU2001269688A1 - Combination containing an antifolate and methylmalonic acid lowering agent - Google Patents

Combination containing an antifolate and methylmalonic acid lowering agent

Info

Publication number
AU2001269688A1
AU2001269688A1 AU2001269688A AU6968801A AU2001269688A1 AU 2001269688 A1 AU2001269688 A1 AU 2001269688A1 AU 2001269688 A AU2001269688 A AU 2001269688A AU 6968801 A AU6968801 A AU 6968801A AU 2001269688 A1 AU2001269688 A1 AU 2001269688A1
Authority
AU
Australia
Prior art keywords
antifolate
lowering agent
methylmalonic acid
acid lowering
combination containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001269688A
Other languages
English (en)
Inventor
Clet Niyikiza
Paolo Paoletti
James Jacob Rusthoven
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27396105&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2001269688(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2001269688A1 publication Critical patent/AU2001269688A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Detergent Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2001269688A 2000-06-30 2001-06-15 Combination containing an antifolate and methylmalonic acid lowering agent Abandoned AU2001269688A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US21531000P 2000-06-30 2000-06-30
US60/215,310 2000-06-30
US23585900P 2000-09-27 2000-09-27
US60/235,859 2000-09-27
US28444801P 2001-04-18 2001-04-18
US60/284,448 2001-04-18
PCT/US2001/014860 WO2002002093A2 (en) 2000-06-30 2001-06-15 Combination containing an antifolate and methylmalonic acid lowering agent

Publications (1)

Publication Number Publication Date
AU2001269688A1 true AU2001269688A1 (en) 2002-01-14

Family

ID=27396105

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001269688A Abandoned AU2001269688A1 (en) 2000-06-30 2001-06-15 Combination containing an antifolate and methylmalonic acid lowering agent

Country Status (11)

Country Link
US (4) US7053065B2 (enExample)
EP (1) EP1313508B1 (enExample)
JP (7) JP5102928B2 (enExample)
AT (1) ATE359823T1 (enExample)
AU (1) AU2001269688A1 (enExample)
CY (1) CY1107649T1 (enExample)
DE (1) DE60127970T2 (enExample)
DK (1) DK1313508T5 (enExample)
ES (1) ES2284660T3 (enExample)
PT (1) PT1313508E (enExample)
WO (1) WO2002002093A2 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1313508B1 (en) * 2000-06-30 2007-04-18 Eli Lilly And Company Combination containing an antifolate and methylmalonic acid lowering agent
DK1874821T3 (da) 2005-04-26 2013-07-08 Trion Pharma Gmbh Kombination af antistoffer med glykokortikoider til behandling af kræft
EP1976530A1 (en) * 2006-01-12 2008-10-08 Novartis AG Combination of mtor inhibitor and antipolate compound
WO2010021843A1 (en) * 2008-08-20 2010-02-25 Eli Lilly And Company Use of antifolates in patients with detectable levels of tff-1 for the cancer treatment
WO2010138955A2 (en) 2009-05-29 2010-12-02 University Of Florida Research Foundation, Inc. Methods and compositions for treating neoplasia
JP5899241B2 (ja) 2010-12-21 2016-04-06 ネクター セラピューティクス ペメトレキセドベースの化合物のマルチアームポリマープロドラッグコンジュゲート
EP3210629A1 (en) 2012-05-30 2017-08-30 Fresenius Kabi Oncology Ltd Pharmaceutical composition of pemetrexed
CA2948601A1 (en) 2014-06-04 2015-12-10 Thomas Helledays Stiftelse For Medicinsk Forskning Mth1 inhibitors for treatment of inflammatory and autoimmune conditions
CA3177726A1 (en) 2015-05-21 2016-11-24 Musculoskeletal Transplant Foundation Modified demineralized cortical bone fibers
EP3328387B1 (en) * 2015-07-30 2020-07-22 Expression Pathology, Inc. Quantifying fr- and gart proteins for optimal cancer therapy
ES2994931T3 (en) * 2015-12-07 2025-02-04 General Oncology Inc Combination for the effective treatment of metastatic cancer in patients
CN120939250A (zh) 2016-08-12 2025-11-14 L.E.A.F.控股集团公司 聚谷氨酸化抗叶酸剂及其用途
WO2018031967A1 (en) 2016-08-12 2018-02-15 L.E.A.F. Holdings Group Llc Polyglutamated antifolates and uses thereof
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
ES2914123T3 (es) 2017-01-09 2022-06-07 Shuttle Pharmaceuticals Inc Inhibidores selectivos de la histona desacetilasa para el tratamiento de una enfermedad humana
ES2983284T3 (es) 2018-01-09 2024-10-22 Shuttle Pharmaceuticals Inc Inhibidores selectivos de histona deacetilasa para el tratamiento de enfermedades humanas
US12239734B2 (en) 2018-02-07 2025-03-04 L.E.A.F. Holdings Group Llc Gamma polyglutamated raltitrexed and uses thereof
CN111954530A (zh) 2018-02-07 2020-11-17 L.E.A.F.控股集团公司 γ聚谷氨酸化培美曲塞及其用途
EP3749313A4 (en) 2018-02-07 2022-03-16 L.E.A.F Holdings Group LLC ALPHA-POLYGLUTAMATE ANTIFOLATES AND ASSOCIATED USES
US11730738B2 (en) 2018-02-07 2023-08-22 L.E.A.F. Holdings Group Llc Alpha polyglutamated pralatrexate and uses thereof
US12220431B2 (en) 2018-02-07 2025-02-11 L.E.A.F. Holdings Group Llc Gamma polyglutamated antifolates and uses thereof
CA3090506A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated tetrahydrofolates and uses thereof
WO2019157138A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated pemetrexed and uses thereof
WO2019157123A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated aminopterin and uses thereof
WO2019157133A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated raltitrexed and uses thereof
US12246019B2 (en) 2018-02-07 2025-03-11 L.E.A.F. Holdings Group Llc Alpha polyglutamated lometrexol and uses thereof
JP7491573B2 (ja) 2018-02-07 2024-05-28 エル．イー．エー．エフ． ホールディングス グループ エルエルシー アルファポリグルタミン酸化メトトレキセートおよびその使用
CA3090943A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated aminopterin and uses thereof
CN111936145A (zh) 2018-02-14 2020-11-13 L.E.A.F.控股集团公司 γ聚谷氨酸化氨甲蝶呤及其用途
EP3752156A4 (en) 2018-02-14 2021-10-27 L.E.A.F Holdings Group LLC GAMMA-POLYGLUTAMIZED PRALATREXATE AND USES THEREOF
EP3755335A4 (en) 2018-02-14 2022-06-22 L.E.A.F Holdings Group LLC GAMMA POLYGLUTAMIC TETRAHYDROFOLATES AND THEIR USES
CA3090875A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated lometrexol and uses thereof
WO2023177894A1 (en) 2022-03-18 2023-09-21 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and an antimetabolite agent
WO2025247952A1 (en) * 2024-05-30 2025-12-04 Université De Fribourg Inhibition of cyanide overproduction for the therapy of down syndrome and nonketotic hyperglycinemia

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US216350A (en) * 1879-06-10 Improvement in car-replacers
US225030A (en) * 1880-03-02 Rotary engine
US2920015A (en) * 1957-08-27 1960-01-05 Armour & Co Long-acting vitamin b12
CH588505A5 (enExample) * 1972-06-08 1977-06-15 Research Corp
US5563126A (en) * 1986-11-20 1996-10-08 Metabolite Laboratories Method for treatment and prevention of deficiencies of vitamins B12, folic acid, and B6
US5405839A (en) * 1989-02-28 1995-04-11 Teijin Limited Vitamin B12 derivative, preparation process thereof, and use thereof
JP2962755B2 (ja) * 1989-02-28 1999-10-12 帝人株式会社 新規ビタミンｂ▲下１▼▲下２▼誘導体、その製造方法並びにその用途
KR0162654B1 (ko) * 1989-12-11 1998-11-16 알렌 제이. 시니스갤리 N-(피롤로[2,3-d]피리미딘-3-일아크릴)-글루타민산 유도체
AU640524B2 (en) * 1991-03-29 1993-08-26 Eli Lilly And Company Use of folic acid for reducing the toxicity of antitumour antifolate agents and methods for treating tumours
JPH05163160A (ja) 1991-12-13 1993-06-29 Snow Brand Milk Prod Co Ltd 免疫低下に伴う感染症の予防及び治療用栄養剤
US6207651B1 (en) 1996-08-02 2001-03-27 Metabolite Laboratories Method for treatment and prevention of deficiencies of vitamins B12, folic acid, and B6
JPH10502334A (ja) 1994-04-08 1998-03-03 レセプタゲン・コーポレーション 受容体調節剤およびこれに関連した方法
WO1996012181A1 (en) * 1994-10-12 1996-04-25 Research & Diagnostics Systems, Inc. Reticulocyte assay control
EP1313508B1 (en) * 2000-06-30 2007-04-18 Eli Lilly And Company Combination containing an antifolate and methylmalonic acid lowering agent
US20040005311A1 (en) * 2001-07-20 2004-01-08 Pitman Bradford D. Dietary supplement compositions

Also Published As

Publication number Publication date
CY1107649T1 (el) 2013-04-18
JP2014005304A (ja) 2014-01-16
JP2004501964A (ja) 2004-01-22
US20060079480A1 (en) 2006-04-13
US20030212038A1 (en) 2003-11-13
ATE359823T1 (de) 2007-05-15
US20080032948A1 (en) 2008-02-07
JP2020117536A (ja) 2020-08-06
WO2002002093A2 (en) 2002-01-10
DE60127970D1 (de) 2007-05-31
JP2018197265A (ja) 2018-12-13
JP2012180381A (ja) 2012-09-20
JP5102928B2 (ja) 2012-12-19
US7053065B2 (en) 2006-05-30
US20100210583A1 (en) 2010-08-19
JP2017019852A (ja) 2017-01-26
EP1313508B1 (en) 2007-04-18
JP5469706B2 (ja) 2014-04-16
ES2284660T3 (es) 2007-11-16
DE60127970T2 (de) 2007-12-20
DK1313508T5 (da) 2017-03-20
PT1313508E (pt) 2007-06-21
EP1313508A2 (en) 2003-05-28
DK1313508T3 (da) 2007-08-06
JP2015178501A (ja) 2015-10-08
WO2002002093A3 (en) 2003-02-06
US7772209B2 (en) 2010-08-10

Similar Documents

Publication Publication Date Title
AU2001269688A1 (en) Combination containing an antifolate and methylmalonic acid lowering agent
WO2001068138A3 (en) Intradermal-penetration agents for topical local anesthetic administration
AU2002245302A1 (en) Methods of using and compositions comprising sibutramine metabolites optionally in combination with other pharmacologically active compounds
BR9812289A (pt) Combinação de tampão catamenial e dispositivo de inserção e processo de produção
AU3104301A (en) Compositions and methods to effect the release profile in the transdermal administration of active agents
AU2002230642A1 (en) Proton generating catheters and methods for their use
WO2002005800A3 (en) Compositions for sustained release of analgesic agents, and methods of making and using the same
AU2001286578A1 (en) Topical antioxidant having vitamin c and method of combination with topical agent by user
WO2000011971A3 (en) Fiber and vitamin-fortified beverage
MXPA03002207A (es) Derivados de acido 2-amino-2-alquil-5-heptenoico y -heptinoico utiles como inhibidores de la oxido nitrico sintasa.
AU5905400A (en) Methods and compositions for delivery and retention of active agents to lymph nodes
AU2002210575A1 (en) Novel medicament compositions based on anticholinergics and corticosteroids
AU7914600A (en) The use of baclofen in the treatment of alcohol withdrawal syndrome and to promote alcohol abstinence in alcoholics
IS6581A (is) Samsetning sem eykur hreyfanleika
WO2001085188A3 (en) Use of echinacea as a hematinic agent
WO2001043748A3 (en) Implant composition containing melengestrol acetate and trenbolone acetate
ZA200301459B (en) Infusion of ciprofloxacin having reduced acid content and being stable in storage.
AU4874301A (en) Medicinal compositions containing camptothecin derivative and ph regulating agent
MXPA03002211A (es) Derivados de acido 2-amino-2-alquil-4-heptenoico y heptinoico utiles como inhibidores de la oxido nitrico sintasa.
WO2002022558A3 (en) 2-amino-2-alkyl-3 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors
WO2003053353A3 (en) Administration of vasopeptidase inhibitors to reduce pulse pressure
YU79802A (sh) Formulacija sa aktivnošću mobilizacije
AU7370798A (en) Compositions and methods of therapy for igf-i-responsive conditions
AU2001267435A1 (en) Plaster containing estrogen, with an active agent reservoir based on ethylcellulose, polyoxyethylene lauryl alcohol and an ethylene-vinylacetate-vinylpyrrolidone copolymer
SI1313508T1 (sl) Sestava, ki vsebuje antifolat in sredstvo za zniĹľevanje metilmalonske kisline